SavedAdd your journal

Journals / BEYOGLU EYE JOURNAL / 2020 / Cilt: 5 - Sayı: 1

The Efficacy of Single-Dose Intravitreal Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-VEGF Therapy: Real-Life Results

Mert ŞİMŞEK
Mehmet CİTİRİK
Serdar ÖZATEŞ
Ali Kemal TEKİN
Dilara ÖZKOYUNCU
Pages
43–48
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After the IDI injection, BCVA value increased (p 50% patients in the sixth month after the first injection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To investigate the efficacy, safety, and side effect profiles of a single-dose intravitreal dexamethasone implant (IDI, Ozurdex) in patients with diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) therapy.
📊
Key Findings & Data:Methods: This study included 101 eyes of 78 diabetic patients with DME that remained persistent despite administering at least six doses of anti-VEGF therapy.
💡
Conclusion & Impact:After the IDI injection, BCVA value increased (p 50% patients in the sixth month after the first injection.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: To investigate the efficacy, safety, and side effect profiles of a single-dose intravitreal dexamethasone implant (IDI, Ozurdex) in patients with diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) therapy. Methods: This study included 101 eyes of 78 diabetic patients with DME that remained persistent despite administering at least six doses of anti-VEGF therapy. The patients were evaluated at baseline and were followed up monthly until the sixth month after the IDI injection. The primary outcomes were central foveal thickness (CFT) and best-corrected visual acuity (BCVA). Results: The mean number of anti-VEGF injection administered to patients was 6.50±0.33. One month after the last injection, the response to treatment was evaluated. IDI injection was performed approximately 1.14±0.08 months after the last anti-VEGF injection. After the IDI injection, BCVA value increased (p 50% patients in the sixth month after the first injection.

🔖

Cite This Article

ŞİMŞEK, M., CİTİRİK, M., ÖZATEŞ, S., TEKİN, A. K., ÖZKOYUNCU, D. (2020). The Efficacy of Single-Dose Intravitreal Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-VEGF Therapy: Real-Life Results. BEYOGLU EYE JOURNAL, Cilt: 5 - Sayı: 1, 43–48. https://ajindex.com/articles/167082

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Patelli F, Radice P, Giacomotti E. Diabetic macular edema. Dev Ophthalmol 2014;54:164–73
  2. Al Dhibi HA, Arevalo JF. Clinical trials on corticosteroids for diabetic macular edema. World J Diabetes 2013;4:295–302
  3. Agarwal A, Afridi R, Hassan M, Sadiq MA, Sepah YJ, Do DV, et al. Novel therapies in development for diabetic macular edema. Curr Diab Rep 2015;15:75
  4. Gillies MC, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, et al. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology 2011;118:866–72
  5. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447–9
  6. Barikian A, Salti H, Safar A, Mahfoud ZR, Bashshur ZF. Intravitreal dexamethasone implant as adjuvant treatment for bevacizumab- and ranibizumab-resistant neovascular age-related macular degeneration: a prospective pilot study. Retina 2017;37:1337–44
  7. Ozkaya A, Tanir I, Alagoz C, Alkin Z, Taskapili M. Twelve-month outcomes of dexamethasone implant treatment in macular edema secondary to retinal vein occlusion in real life. Beyoglu Eye J 2017;1:24–8
  8. Yang Y, Bailey C, Loewenstein A, Massin P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina 2015;35:2440–9
  9. Kim M, Cho YJ, Lee CH, Lee SC. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections. Eye (Lond) 2016;30:718–25
  10. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 2014;231:141–6
  11. Zucchiatti I, Lattanzio R, Querques G, Querques L, Del Turco C, Cascavilla ML, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012;228:117–22
  12. Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M, Coi L, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013;7:1423–8
  13. Yucel OE, Can E, Ozturk HE, Birinci H, Sullu Y. Dexamethasone implant in chronic diabetic macular edema resistant to intravitreal ranibizumab treatment. Ophthalmic Res 2017;57:161–5